Zai Lab Shares Surge Over 5% in Late Trading as Zoci Receives FDA Fast Track Designation for Extrapulmonary Neuroendocrine Carcinoma

Stock News05-15

Zai Lab (09688) saw its shares climb more than 5% in late trading. At the time of writing, the stock was up 4.89% to HK$16.1, with a turnover of HK$247 million.

The move follows the company's recent announcement that the U.S. FDA has granted Fast Track designation to zocilurtatug pelitecan (zoci, formerly known as ZL-1310), an antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3) with first-in-class potential. The designation is for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs) in patients who have experienced disease progression following first-line standard therapy.

Previously, in May 2025, zoci received FDA Fast Track designation for the treatment of extensive-stage small cell lung cancer (ES-SCLC).

Separately, Zai Lab's partner argenx recently announced that the U.S. FDA has approved label expansions for VYVGART (efgartigimod alfa intravenous infusion) and VYVGART Hytrulo (efgartigimod alfa subcutaneous injection) for the treatment of all adult patients with generalized myasthenia gravis (gMG). Zai Lab secured the rights to efgartigimod in Greater China in January 2021.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment